We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

123 hedge funds and large institutions have $1.21B invested in Verve Therapeutics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

683% more call options, than puts

Call options by funds: $9M | Put options by funds: $1.15M

62% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 29

0.41% more ownership

Funds ownership: 101.26% → 101.68% (+0.41%)

0% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 28

2% less funds holding

Funds holding: 125 → 123 (-2)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

42% less capital invested

Capital invested by funds: $2.08B → $1.21B (-$871M)

Holders
123
Holders Change
-2
Holders Change %
-1.6%
% of All Funds
1.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
28
Increased
47
Reduced
29
Closed
28
Calls
$9M
Puts
$1.15M
Net Calls
+$7.85M
Net Calls Change
-$3.88M

Top Buyers

1
State Street
State Street
Massachusetts
+$44.3M
2
AIM
ARK Investment Management
Florida
+$25.8M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$14.4M
4
APM
Avidity Partners Management
Texas
+$13.8M
5
NAMA
Nikko Asset Management Americas
New York
+$12M

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$26.6M
2
DM
Deerfield Management
New York
-$25.8M
3
PHS
PFM Health Sciences
California
-$25.2M
4
CC
Casdin Capital
New York
-$23.5M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$204M -$11.3M -424,925 -4%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$134M -$15.3M -576,927 -8%
State Street
3
State Street
Massachusetts
$86.5M +$44.3M +1,671,215 +60%
AIM
4
ARK Investment Management
Florida
$84.5M +$25.8M +971,971 +29%
Vanguard Group
5
Vanguard Group
Pennsylvania
$73.8M +$4.06M +153,212 +4%
BlackRock
6
BlackRock
New York
$69.5M +$5.77M +217,864 +6%
CC
7
Casdin Capital
New York
$44.3M -$23.5M -887,596 -28%
Federated Hermes
8
Federated Hermes
Pennsylvania
$40.2M +$8.71M +328,552 +19%
AVM
9
Arch Venture Management
Illinois
$38.9M – – –
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$34.8M +$14.4M +544,834 +43%
JP Morgan Chase
11
JP Morgan Chase
New York
$34.6M -$3.45M -130,028 -7%
APM
12
Avidity Partners Management
Texas
$30.3M +$13.8M +522,294 +50%
BBA
13
Baker Bros. Advisors
New York
$27.4M – – –
NAMA
14
Nikko Asset Management Americas
New York
$23.8M +$12M +452,750 +58%
Sumitomo Mitsui Trust Group
15
Sumitomo Mitsui Trust Group
Japan
$23.8M +$12M +452,750 +58%
RG
16
Redmile Group
California
$23.6M -$7.5M -283,223 -19%
NHAS
17
Novo Holdings A/S
Denmark
$17.6M – – –
Wellington Management Group
18
Wellington Management Group
Massachusetts
$16.6M -$4.02M -151,606 -15%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$16.4M +$1.72M +65,021 +8%
MB
20
MPM BioImpact
Massachusetts
$15.6M +$4.58M +172,869 +27%
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
$13.4M +$3.97M +150,000 +28%
BI
22
BVF Inc
California
$12.6M – – –
RSCM
23
Rock Springs Capital Management
Maryland
$10.8M – – –
Bank of America
24
Bank of America
North Carolina
$7.84M +$6.92M +261,198 +181%
Northern Trust
25
Northern Trust
Illinois
$7.74M +$290K +10,947 +3%
1
2 3 4 5

VERV Hedge Fund Activity: Q4 2022 in Review

123 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2022, worth a combined $1.21B — down 42% from $2.08B a quarter earlier.

Fund positioning in VERV was balanced in Q4 2022: 28 funds opened new positions, 28 closed out, 47 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $44.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $26.6M sold.

  • 123 institutional investors held Verve Therapeutics (VERV) as of Q4 2022, down from 125 in Q3 2022.
  • Funds reported $1.21B of Verve Therapeutics stock for Q4 2022, down 42% quarter-over-quarter.
  • 28 funds opened new Verve Therapeutics positions in Q4 2022 and 28 closed out, a net change of 0 holders.
  • The largest Verve Therapeutics buyer in Q4 2022 was State Street, an estimated $44.3M added.
  • The largest Verve Therapeutics seller in Q4 2022 was Deep Track Capital, an estimated $26.6M sold.

Based on aggregated 13F filings for Q4 2022.